



ASIAN INVESTMENT SERIES 2018

13 March 2018 KPMG Hong Kong 15-16 March 2018 KPMG Shanghai

HONG KONG BIOTECH
INVEST & PARTNERING

AUSTRALIA-CHINA BIOTECH
INVEST & PARTNERING



Expanesthetics, Inc.

Company Description

Expanesthetics is the global leader in the search for new, improved inhalation general anesthetics. It has an additional program developing novel non-opioid analgesics. Expanesthetics is utilizing a fundamentally new understanding of how inhalation anesthetics work to identify new and better drugs. With global headquarters in California, the company plans to establish its Asia Pacific operations in Melbourne. The company has a world-class board of directors, scientific and clinical advisory boards, scores of anesthesiologist and other physician investors, and ongoing discussions and collaborations with many of the important participants in this space.

Pipeline and Developments

Expanesthetics is developing multiple general anesthetic candidates and has ongoing discussions and collaborations with many of the important participants in the field of anesthesia. It is also developing a new non-opioid and non-NSAID analgesic (EXP-PN-01) that has demonstrated exciting preclinical results including in higher mammals. There has been significant interest in the potential of this program in both animal and human indications.

The next US\$15 million in investment capital is budgeted to enable preclinical evaluation of multiple general anesthetic candidates and to achieve first-in-human clinical results with one general anesthetic in Australia in late 2020. It is also budgeted to achieve an important business development milestone in the analgesic program.

What we are looking for:

This investment should be considered by those investors seeking high risk opportunities with commensurate potential returns and a time horizon of 4-6 years. Expanesthetics is ready to talk with family office or high-net-worth investors with an interest in better general anesthesia, increased access to surgery, lower healthcare costs, or new pain medicines who are looking to join an already strong global team.

Contact:

Name: Mark Holman

Position: Chairman and CEO

Company: Expanesthetics, Inc.

Address: 1260 Lake Blvd. Suite 231, Davis, CA 95616, USA

Website: <https://expanesthetics.com/>

Phone: +1 (530) 298-7201 ext. 707

Email: mark.holman@expanesthetics.com

For more information, please visit www.australiabiotechinvest.com.au



Follow us for the latest event update #AusBioInv